Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance

Ragia, Georgia; Giannakopoulou, Efstathia; Karaglani, Makrina; Karantza, Ioanna-Maria; Tavridou, Anna; Manolopoulos, Vangelis G.

doi:10.1515/dmdi-2014-0006

Cited by 15 publications

(6 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The two ABCB1 polymorphisms were in linkage disequilibrium (D' = 0.846, r 2 = 0.660) as expected, and their respective genotype frequencies were similar to those published previously for the general population in Greece and in other Caucasian populations (Gbandi et al, ). The CYP2D6 *3, *4, and xN frequencies were more or less similar to those reported earlier for a Greek population (Ragia et al, ). CYP2D6 *5 and *10 frequencies were not previously reported for the Greek population.…”

Section: Resultssupporting

confidence: 89%

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

Papazisis

Goulas

Sarrigiannidis

et al. 2017

Human Psychopharmacology

View full text Add to dashboard Cite

Objectives: The aim of our study was to examine the association between ABCB1 polymorphisms G2677T/A (rs2032582) and C3435T (rs1045642) and common CYP2D6 variants, with the response to antipsychotic treatment of psychotic patients, in a naturalistic setting, in Greece.Methods: One hundred patients suffering from schizophrenia and other psychotic disorders were included in the study. Dosages were normalized to chlorpromazine equivalents. Response following 1 month of treatment was assessed as either a continuous variable, using the distribution of the corrected Positive and Negative Syndrome Scale percent change, or as a dichotomous variable defined as the number of patients scoring ≥30% from the corrected baseline Positive and Negative Syndrome Scale score. Genotyping was achieved with established polymerase chain reaction-restriction fragment length polymorphism methods.Results: With response treated as a continuous variable, the homozygous recessive rs2032582 genotypes (TT) who were simultaneously carriers of a loss-of-function CYP2D6 allele (*4 or *5) responded significantly worse than the rest of the patients. Comparison of genotype frequencies revealed a statistically significant association of the above combination. No significant association between chlorpromazine equivalents and the tested genotypes was detected. Conclusion:We have detected a possible interaction between ABCB1 and CYP2D6 in affecting response of psychotic patients to drug treatment, in a naturalistic setting.

show abstract

Section: Resultssupporting

confidence: 89%

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

Papazisis

Goulas

Sarrigiannidis

et al. 2017

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…We have further estimated the prevalence of CYP3A4*22 allele in a sample of the Greek population at 5.0%. Our results are in agreement with the reported global allele minor allele frequency (MAF) of 2.5%-6.0% annotated by 1000 genomes and within the MAF range 5.0%-11.2% described for European populations [9,14].…”

Section: Discussionsupporting

confidence: 92%

No effect of CYP3A4 intron 6 C>T polymorphism (*CYP3A4**22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia

Ragia

Kolovou

Tavridou³

et al. 2014

Drug Metabolism and Personalized Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…The wild-type (WT) genotype was excluded from the analysis because of the small number of subjects with this genotype (n = 2) and the lack of crucial data [Hardy-Weinberg equilibrium, p = 0.178]. The frequency of CYP3A5 expressors was in accordance with that previously reported for the Greek population ( Arvanitidis et al , 2007 ; Kolovou et al , 2014 ; Ragia et al , 2014c ). Gender was not associated with the CYP3A5 frequency (p = 0.408).…”

Section: Resultssupporting

confidence: 53%

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin

et al. 2015

Self Cite

View full text Add to dashboard Cite

In this work, we examined the impact of polymorphism in the cytochrome P450 (CYP) 3A5 gene, CYP3A5*1 (6986A > G, rs 776746), on the reduction in the lipid levels caused by simvastatin and atorvastatin. We studied 350 hyperlipidemic patients who received 10-40 mg of atorvastatin (n = 175) or simvastatin (n = 175) daily. Genotyping for CYP3A5 was done by PCR-RFLP analysis. Differences in the lipid profile before and after treatment were expressed as the % difference. The frequency of CYP3A5polymorphism was 13.4% for heterozygotes and 86.6% for homozygotes. Comparison of the responses to same dose of each drug showed that the highest % difference was associated with total cholesterol (TC) in subjects receiving atorvastatin 40 mg compared with simvastatin 40 mg (p = 0.048). However, comparison of the responses to equivalent doses of atorvastatin vs. simvastatin revealed no difference in the % change in any of the lipid parameters examined. In individuals with the same CYP3A5 genotype, a head to head comparison of the efficacy of the same dose of simvastatin vs. atorvastatin revealed an advantage for atorvastatin. For equivalent doses of atorvastatin vs. simvastatin there was no difference in the % change in any of the lipid parameters examined. Within the same genotype there was a significant difference in the % change related to the drug treatment.

show abstract

Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance

Cited by 15 publications

References 79 publications

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

No effect of CYP3A4 intron 6 C>T polymorphism (*CYP3A4**22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin

Contact Info

Product

Resources

About

Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance

Cited by 15 publications

References 79 publications

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic setting

No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin

Contact Info

Product

Resources

About

No effect of CYP3A4 intron 6 C>T polymorphism (*CYP3A4**22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia